Pharvaris to Host Virtual Investor Event on October 23, 2024
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE) attacks, will host a virtual investor event on October 23, 2024, at 10:00 a.m. ET/16:00 CET. The event will focus on:
- Unmet needs in prophylactic and on-demand HAE attack treatment
- Potential of deucrictibant to address these needs
- Current HAE market dynamics
Presenters include medical experts Dr. Michael E. Manning and Dr. Raffi Tachdjian, along with Pharvaris executives Berndt Modig (CEO), Dr. Peng Lu (CMO), and Dr. Wim Souverijns (CCO). A live Q&A session will follow the presentations, and an archived replay will be available for at least 30 days after the event.
Pharvaris (Nasdaq: PHVS), un'azienda biofarmaceutica in fase avanzata che sviluppa nuovi antagonisti orali del recettore bradychinina B2 per gli attacchi di angioedema ereditario (HAE), ospiterà un evento virtuale per gli investitori il 23 ottobre 2024, alle 10:00 ET/16:00 CET. L'evento si concentrerà su:
- Necessità non soddisfatte nel trattamento profilattico e a richiesta degli attacchi HAE
- Potenziale del deucrictibant per rispondere a tali esigenze
- Dinamiche attuali del mercato HAE
I relatori includono esperti medici come il Dr. Michael E. Manning e il Dr. Raffi Tachdjian, insieme ai dirigenti di Pharvaris Berndt Modig (CEO), Dr. Peng Lu (CMO) e Dr. Wim Souverijns (CCO). Seguirà una sessione di domande e risposte dal vivo dopo le presentazioni, e una registrazione archiviata sarà disponibile per almeno 30 giorni dopo l'evento.
Pharvaris (Nasdaq: PHVS), una compañía biofarmacéutica en fase avanzada que desarrolla nuevos antagonistas orales del receptor de bradiquinina B2 para ataques de angioedema hereditario (HAE), llevará a cabo un evento virtual para inversores el 23 de octubre de 2024, a las 10:00 a.m. ET/16:00 CET. El evento se centrará en:
- Necesidades insatisfechas en el tratamiento profiláctico y a demanda de ataques de HAE
- Potencial del deucrictibant para abordar estas necesidades
- Dinamicas actuales del mercado de HAE
Los presentadores incluyen a expertos médicos como el Dr. Michael E. Manning y el Dr. Raffi Tachdjian, junto con los ejecutivos de Pharvaris Berndt Modig (CEO), Dr. Peng Lu (CMO), y Dr. Wim Souverijns (CCO). Se realizará una sesión de preguntas y respuestas en vivo tras las presentaciones, y se dispondrá de una grabación archivada durante al menos 30 días después del evento.
Pharvaris (Nasdaq: PHVS)는 유전성 혈관 부종(HAE) 발작을 위한 새로운 경구 브라디키닌 B2 수용체 길항제를 개발하고 있는 후기 단계의 생명공학 회사로서, 2024년 10월 23일 오전 10시 ET/오후 4시 CET에 가상 투자자 행사를 개최합니다. 이번 행사는 다음과 같은 내용에 중점을 둡니다:
- HAE 발작의 예방 및 필요시 치료에 대한 충족되지 않은 필요
- 이러한 필요를 충족시키기 위한 deucrictibant의 잠재력
- 현재 HAE 시장의 역학
발표자에는 의학 전문가인 Michael E. Manning 박사와 Raffi Tachdjian 박사, 그리고 Pharvaris의 임원인 Berndt Modig(CEO), Peng Lu 박사(CMO), Wim Souverijns 박사(CCO)가 포함됩니다. 발표 후에는 실시간 질의응답 세션이 진행되며, 행사 후 최소 30일 동안 아카이브된 재생이 제공됩니다.
Pharvaris (Nasdaq: PHVS), une société biopharmaceutique en phase avancée développant de nouveaux antagonistes oraux des récepteurs de bradykinine B2 pour les attaques d'angiœdème héréditaire (HAE), tiendra un événement virtuel pour investisseurs le 23 octobre 2024, à 10h00 ET/16h00 CET. L'événement se concentrera sur :
- Les besoins non satisfaits dans le traitement prophylactique et à la demande des attaques d'HAE
- Le potentiel du deucrictibant pour répondre à ces besoins
- Dynamique actuelle du marché de l'HAE
Les présentateurs comprendront des experts médicaux tels que Dr. Michael E. Manning et Dr. Raffi Tachdjian, ainsi que les dirigeants de Pharvaris Berndt Modig (PDG), Dr. Peng Lu (CMO) et Dr. Wim Souverijns (CCO). Une session de questions-réponses en direct suivra les présentations, et un replay archivé sera disponible pendant au moins 30 jours après l'événement.
Pharvaris (Nasdaq: PHVS) ist ein fortgeschrittenes biopharmazeutisches Unternehmen, das neuartige orale Bradykinin-B2-Rezeptorantagonisten zur Behandlung von erblichem Angioödem (HAE)-Anfällen entwickelt. Am 23. Oktober 2024 um 10:00 Uhr ET/16:00 Uhr CET findet eine virtuelle Investorenveranstaltung statt. Die Veranstaltung wird sich auf folgende Punkte konzentrieren:
- Unerfüllte Bedürfnisse in der prophylaktischen und bedarfsorientierten Behandlung von HAE-Anfällen
- Das Potenzial von Deucrictibant zur Deckung dieser Bedürfnisse
- Aktuelle Marktdynamik von HAE
Zu den Referenten gehören medizinische Experten wie Dr. Michael E. Manning und Dr. Raffi Tachdjian sowie die Pharvaris-Führungskräfte Berndt Modig (CEO), Dr. Peng Lu (CMO) und Dr. Wim Souverijns (CCO). Nach den Präsentationen wird eine Live-Q&A-Session stattfinden, und eine archivierte Wiederholung wird mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced it will host a virtual investor event to discuss the unmet need in both the prophylactic and on-demand treatment of HAE attacks, the potential of deucrictibant to address to needs, and the current HAE market dynamics, on Wednesday, October 23, 2024, at 10:00 a.m. ET/16:00 CET. To register, click here.
Presenters of the event are:
- Michael E. Manning, M.D., Allergy, Asthma & Immunology Associates, LTD
- Raffi Tachdjian, M.D., MPH, David Geffen School of Medicine at the University of California, Los Angeles (UCLA)
- Berndt Modig, Chief Executive Officer of Pharvaris
- Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris
- Wim Souverijns, Ph.D., Chief Commercial Officer of Pharvaris
A live question and answer session will follow the formal presentations. Following the live event, an archived replay will be available for at least 30 days after the event.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of bradykinin-mediated angioedema effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both prophylactically and on-demand. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks in the coming months. For more information, visit https://pharvaris.com/.
FAQ
When is Pharvaris (PHVS) hosting its virtual investor event?
What topics will be discussed at Pharvaris' (PHVS) investor event?
Who are the presenters at Pharvaris' (PHVS) upcoming investor event?
What is Pharvaris (PHVS) developing for hereditary angioedema (HAE)?
Will there be a Q&A session at Pharvaris' (PHVS) investor event?
